| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 175,3 k € | -1.8% | 178,6 k € | -11.9% | 202,7 k € | +11.3% | 182,0 k € | +24.4% | 146,4 k € | -5.1% | 154,2 k € | +63.7% | 94,2 k € | -0.2% | 94,4 k € | -17.4% | 114,3 k € | +274.1% | 30,6 k € | -64.2% | 85,3 k € | |
| EBITDA | 169,8 k € | -2.8% | 174,6 k € | -12.2% | 199,0 k € | +11.2% | 179,0 k € | +23.3% | 145,2 k € | -4.7% | 152,4 k € | +66.8% | 91,4 k € | -2.2% | 93,4 k € | -17.3% | 112,9 k € | +281.7% | 29,6 k € | -64.4% | 83,0 k € | |
| Operating profit | 113,2 k € | -6.5% | 121,1 k € | -25.6% | 162,7 k € | +13.7% | 143,0 k € | +30.9% | 109,3 k € | -6.2% | 116,5 k € | +35.5% | 86,0 k € | -1.1% | 86,9 k € | -18.2% | 106,2 k € | +380.7% | 22,1 k € | -67.6% | 68,2 k € | |
| Profit/loss | 160,0 k € | -15.8% | 190,1 k € | +21.4% | 156,6 k € | +73.2% | 90,4 k € | +40.1% | 64,5 k € | -23.1% | 83,9 k € | +24.4% | 67,4 k € | +35.3% | 49,8 k € | -20.9% | 63,0 k € | +370.5% | 13,4 k € | -71.5% | 47,0 k € | |
| Equity | 731,7 k € | +28.0% | 571,7 k € | +32.5% | 431,6 k € | +9.3% | 395,0 k € | +14.6% | 344,6 k € | +23.0% | 280,1 k € | +47.4% | 190,0 k € | +17.6% | 161,5 k € | +44.6% | 111,7 k € | +129.1% | 48,8 k € | -0.9% | 49,2 k € | |
| Total assets | 1,7 M € | -3.0% | 1,7 M € | +3.6% | 1,7 M € | +0.4% | 1,7 M € | -1.4% | 1,7 M € | -2.0% | 1,7 M € | +3.4% | 1,7 M € | +49.3% | 1,1 M € | -0.8% | 1,1 M € | +1455.3% | 73,0 k € | -15.2% | 86,1 k € | |
| Cash | 42,7 k € | -21.9% | 54,7 k € | -27.8% | 75,7 k € | +93.0% | 39,2 k € | +22.2% | 32,1 k € | +24.1% | 25,9 k € | -55.9% | 58,6 k € | +307.6% | 14,4 k € | -13.7% | 16,7 k € | -70.1% | 55,8 k € | +21.3% | 46,0 k € | |
| Debts | 958,7 k € | -18.0% | 1,2 M € | -6.4% | 1,2 M € | -2.3% | 1,3 M € | -5.6% | 1,4 M € | -6.9% | 1,5 M € | -2.2% | 1,5 M € | +54.7% | 961,4 k € | -5.6% | 1,0 M € | +4394.6% | 22,7 k € | -36.0% | 35,4 k € | |
Private limited company · Waregem · incorporated on 04/07/2013
Private limited company profitable and well capitalised. Cash position declining (-21.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
VVM Pharma Invest is a Private limited company incorporated in 2013. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Waregem.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette